DBV Technologies Valuation

Is 0QAJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QAJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0QAJ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0QAJ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QAJ?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 0QAJ. This is calculated by dividing 0QAJ's market cap by their current preferred multiple.
What is 0QAJ's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

0QAJ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	-0.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0QAJ's PS Ratio compare to its peers?

The above table shows the PS ratio for 0QAJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.4x
TRX Tissue Regenix Group	1.8x	15.1%	UK£43.5m
AREC Arecor Therapeutics	5.8x	35.0%	UK£28.3m
AVCT Avacta Group	7.8x	14.3%	UK£177.3m
BVXP Bioventix	14.3x	n/a	UK£194.4m
0QAJ DBV Technologies	5.8x	54.6%	€74.8m

Price-To-Sales vs Peers: 0QAJ is good value based on its Price-To-Sales Ratio (5.8x) compared to the peer average (7.4x).

Price to Earnings Ratio vs Industry

How does 0QAJ's PE Ratio compare vs other companies in the GB Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	37.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	37.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 0QAJ is good value based on its Price-To-Sales Ratio (5.8x) compared to the European Biotechs industry average (8.9x).

Price to Sales Ratio vs Fair Ratio

What is 0QAJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QAJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.8x
Fair PS Ratio	11.7x

Price-To-Sales vs Fair Ratio: 0QAJ is good value based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (11.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.